AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12904425 — intervention group
Group type: COMPARATOR
Intervention: Empirical therapy
Number of subjects: 28
Study 10671850 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 10 mg made up to 2 ml with saline
Number of subjects: 90
Study 10671850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac with venous occlusion for 2 min
Number of subjects: 90
Study 10671850 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 90
Study 9115060 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of cyclosporine and diclofenac
Number of subjects: 0
Study 9115060 — intervention group
Group type: COMPARATOR
Intervention: Coadministration of cyclosporine and NSAIDs (excluding diclofenac)
Number of subjects: 0
Study 1490503 — intervention group
Group type: EXPERIMENTAL
Intervention: Madopar HBS
Number of subjects: 18
Study 1490503 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet CR
Number of subjects: 18
Study 1490503 — intervention group
Group type: COMPARATOR
Intervention: Conventional Madopar capsules
Number of subjects: 18
Study 1490503 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Madopar
Number of subjects: 18
Study 3839263 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 5‐fluorouracil, doxorubicin, and mitomycin C (FAM)
Number of subjects: 186
Study 3839263 — intervention group
Group type: COMPARATOR
Intervention: Combined methotrexate, doxorubicin, cyclophosphamide, and lomustine (MACC)
Number of subjects: 186
Study 3839263 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of both regimens
Number of subjects: 186
Study 3839263 — intervention group
Group type: COMPARATOR
Intervention: MACC in adenocarcinoma
Number of subjects: 186
Study 3839263 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM in squamous-cell carcinoma
Number of subjects: 186
Study 3839263 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity comparison
Number of subjects: 186
Study 29852851 — intervention group
Group type: COMPARATOR
Intervention: 3% saline (SAL)
Number of subjects: 10
Study 29852851 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5M sodium lactate (LAC)
Number of subjects: 10
Study 27021606 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH ERCT 40 mg
Number of subjects: 33
Study 27021606 — intervention group
Group type: COMPARATOR
Intervention: IR MPH 40 mg
Number of subjects: 33
Study 27021606 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 33
Study 25328688 — intervention group
Group type: EXPERIMENTAL
Intervention: Join the Healthy Boat programme
Number of subjects: 1943
Study 25328688 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1943
Study 23554054 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (400μg/day, n = 6)
Number of subjects: 14
Study 23554054 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 14
Study 23554054 — intervention group
Group type: COMPARATOR
Intervention: Folic acid compared to placebo
Number of subjects: 14
Study 19952781 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin 1.6 mg per day for 16 weeks
Number of subjects: 181
Study 19952781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 18782344 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (up to 15 mg)
Number of subjects: 30
Study 18782344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16640610 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 351
Study 16640610 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ) + Sulphadoxine-Pyrimethamine (SP)
Number of subjects: 351
Study 16640610 — intervention group
Group type: COMPARATOR
Intervention: Sulphadoxine-Pyrimethamine (SP)
Number of subjects: 351
Study 16640610 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ) or Amodiaquine + Sulphadoxine-Pyrimethamine (SP)
Number of subjects: 351
Study 16640610 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine + Sulphadoxine-Pyrimethamine (SP)
Number of subjects: 351
Study 12745487 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment and nicotine replacement therapy (gum, patch, or inhaler) to reduce smoking by 50% over 4 weeks
Number of subjects: 67
Study 12745487 — intervention group
Group type: COMPARATOR
Intervention: Usual-care (brief advice to quit and nicotine replacement if they decided to quit)
Number of subjects: 67
Study 11910264 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTP 100 mg with carbidopa 100 mg and 50 mg
Number of subjects: 12
Study 11910264 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTP 100 mg
Number of subjects: 12
Study 11910264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11910264 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTP 200 mg
Number of subjects: 12
Study 10328437 — intervention group
Group type: COMPARATOR
Intervention: recombinant human erythropoietin (rhEPO)
Number of subjects: 13
Study 10328437 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant canine erythropoietin (rcEPO)
Number of subjects: 13
Study 7488373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin hydrochloride (200 mg/mL), 24 patients
Number of subjects: 44
Study 7488373 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin sulfate (5 mg/mL), 20 patients
Number of subjects: 44
Study 2031210 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital doctors providing information about illness and death to cancer patients
Number of subjects: 639
Study 2031210 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital doctors' communication practices
Number of subjects: 639
Study 2031210 — intervention group
Group type: EXPERIMENTAL
Intervention: Support and information provided by professionals to relatives
Number of subjects: 639
Study 2031210 — intervention group
Group type: EXPERIMENTAL
Intervention: Role of hospital doctors vs general practitioners in providing information
Number of subjects: 639
Study 2031210 — intervention group
Group type: EXPERIMENTAL
Intervention: Situations of 'closed awareness'
Number of subjects: 639
Study 2031210 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses and hospice practitioners' involvement in breaking bad news
Number of subjects: 639
Study 2031210 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatives' perceptions of communication
Number of subjects: 639
Study 2031210 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaps in information provided to relatives
Number of subjects: 639
Study 7036816 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir at 750 mg/m2 body surface area per day for 7 days
Number of subjects: 34
Study 7036816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 7036816 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir
Number of subjects: 34
Study 31411099 — intervention group
Group type: EXPERIMENTAL
Intervention: GONAL‐f® injector
Number of subjects: 180
Study 31411099 — intervention group
Group type: COMPARATOR
Intervention: Bemfola® injector
Number of subjects: 180
Study 31411099 — intervention group
Group type: COMPARATOR
Intervention: Rekovelle® injector
Number of subjects: 180
Study 31411099 — intervention group
Group type: COMPARATOR
Intervention: Ovaleap® injector
Number of subjects: 180
Study 27859353 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intervention (8 session group Triple P)
Number of subjects: 69
Study 27859353 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention (3 session discussion group)
Number of subjects: 69
Study 27859353 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 69
Study 27859353 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief and standard interventions
Number of subjects: 69
Study 24909241 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen bone (FFB) allograft in chips
Number of subjects: 20
Study 24909241 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone from the mandibular ramus
Number of subjects: 20
Study 25093728 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational poster displayed in classrooms for 2 weeks (intervention group, 364 students)
Number of subjects: 671
Study 25093728 — intervention group
Group type: COMPARATOR
Intervention: No display of educational posters (control group, 305 students)
Number of subjects: 671
Study 22004689 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg nightly for 12 months
Number of subjects: 33
Study 22004689 — intervention group
Group type: COMPARATOR
Intervention: Placebo nightly for 12 months
Number of subjects: 33
Study 19179556 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin and fluorouracil (TPF)
Number of subjects: 166
Study 19179556 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and fluorouracil (PF)
Number of subjects: 166
Study 17242100 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% (w/v)
Number of subjects: 80
Study 17242100 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25% (w/v)
Number of subjects: 80
Study 15614540 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpalpebral tonometer TGDc-01
Number of subjects: 103
Study 15614540 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometry
Number of subjects: 103
Study 12185774 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist nursing intervention; details on dosage and duration not available.
Number of subjects: 0
Study 12185774 — intervention group
Group type: COMPARATOR
Intervention: Control group; details not specified.
Number of subjects: 0
Study 9526211 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg enoxaparin subcutaneously once per day
Number of subjects: 246
Study 9526211 — intervention group
Group type: COMPARATOR
Intervention: 5,000 IU heparin sodium subcutaneously 3 times daily (increased to 7,500 IU if PTT did not reach 40 seconds)
Number of subjects: 246
Study 8015647 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin
Number of subjects: 17
Study 2718920 — intervention group
Group type: EXPERIMENTAL
Intervention: Low selenium intake (18 +/- 1 micrograms/d) for 30 days
Number of subjects: 16
Study 2718920 — intervention group
Group type: COMPARATOR
Intervention: Adequate selenium intake (119 +/- 1 micrograms/d)
Number of subjects: 16
Study 1158187 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagotomy and antrectomy
Number of subjects: 0
Study 1158187 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy
Number of subjects: 0
Study 1158187 — intervention group
Group type: COMPARATOR
Intervention: Posture effect on gastric emptying
Number of subjects: 0
Study 30765948 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification (PE)
Number of subjects: 91
Study 30765948 — intervention group
Group type: COMPARATOR
Intervention: Phacotrabeculectomy (PT)
Number of subjects: 91
Study 26567123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified treatment for type 2 diabetes
Number of subjects: 3810
Study 26567123 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin use
Number of subjects: 3810
Study 26567123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipeptidyl peptidase‐4 inhibitors
Number of subjects: 3810
Study 26567123 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe episodes of hypoglycaemia
Number of subjects: 3810
Study 26567123 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐severe episodes of hypoglycaemia
Number of subjects: 3810
Study 26391130 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (quartiles 2-4)
Number of subjects: 396
Study 26391130 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (quartiles 2-4)
Number of subjects: 396
Study 26391130 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble intercellular adhesion molecule-1 (quartiles 2-4)
Number of subjects: 396
Study 26391130 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer (quartiles 2-4)
Number of subjects: 396
Study 26391130 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (multivariable adjustment)
Number of subjects: 396
Study 26391130 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (multivariable adjustment)
Number of subjects: 396
Study 26391130 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble intercellular adhesion molecule-1 (multivariable adjustment)
Number of subjects: 396
Study 26391130 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer (multivariable adjustment)
Number of subjects: 396
Study 23070939 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered solution with mild alkalinity (pH 7.2-7.4)
Number of subjects: 36
Study 23070939 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered solution with alkalinity (pH 8.2-8.4)
Number of subjects: 36
Study 23070939 — intervention group
Group type: COMPARATOR
Intervention: Nonbuffered solution (pH 6.2-6.4)
Number of subjects: 36
Study 20571360 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure variability episodes outside a blood pressure range (higher than 135 or lower than 95 mmHg)
Number of subjects: 5038
Study 18381307 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate injection
Number of subjects: 90
Study 18381307 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow injection
Number of subjects: 90
Study 18381307 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 90
Study 16614408 — intervention group
Group type: EXPERIMENTAL
Intervention: (n‐3) fatty acids supplementation (3.6 g (n‐3) fatty acids/d)
Number of subjects: 162
Study 16614408 — intervention group
Group type: EXPERIMENTAL
Intervention: (n‐3) fatty acids supplementation
Number of subjects: 162
Study 16614408 — intervention group
Group type: EXPERIMENTAL
Intervention: Background diet with high proportion of MUFA
Number of subjects: 162
Study 12574881 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g ceftriaxone i.v. 30 min preoperatively
Number of subjects: 83
Study 12574881 — intervention group
Group type: COMPARATOR
Intervention: No study medication (control)
Number of subjects: 83
Study 10936741 — intervention group
Group type: EXPERIMENTAL
Intervention: Menorest
Number of subjects: 0
Study 10936741 — intervention group
Group type: COMPARATOR
Intervention: Climara
Number of subjects: 0
Study 10936741 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 0
Study 9148635 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive temporary clipping of the carrying arteries in anterior connecting arterial aneurysms
Number of subjects: 0
Study 9148635 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive temporary clipping of the carrying arteries in middle cerebral arterial aneurysms
Number of subjects: 0
Study 8420681 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 125 and Transvaginal Ultrasound (TVUS)
Number of subjects: 74000
Study 8420681 — intervention group
Group type: COMPARATOR
Intervention: Routine medical care
Number of subjects: 74000
Study 3080781 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 27
Study 3080781 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 27
Study 3080781 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 27
Study 3080781 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-endogenous depressives
Number of subjects: 27
Study 3080781 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous depressives
Number of subjects: 27
Study 3080781 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram and Maprotiline
Number of subjects: 27
Study 2523228 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (0.04 micrograms kg‐1 min‐1)
Number of subjects: 8
Study 2523228 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (0.025 micrograms kg‐1 min‐1)
Number of subjects: 8
Study 2523228 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor with noradrenaline
Number of subjects: 8
Study 30380926 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected young transgender women
Number of subjects: 0
Study 28333180 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS disease label
Number of subjects: 181
Study 28333180 — intervention group
Group type: COMPARATOR
Intervention: Overdiagnosis information
Number of subjects: 181
Study 24621069 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g of a proprietary mixture of non-starch polysaccharides (NSPs) (Ambrotose® complex)
Number of subjects: 73
Study 24621069 — intervention group
Group type: COMPARATOR
Intervention: Rice flour placebo
Number of subjects: 73
Study 24621069 — intervention group
Group type: COMPARATOR
Intervention: Sucrose control
Number of subjects: 73
Study 22700845 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of clinical staff and provision of tailor‐made information resources with a change in clinic policy to universal HIV testing
Number of subjects: 1315
Study 22700845 — intervention group
Group type: COMPARATOR
Intervention: Training of clinical staff and provision of tailor‐made information resources without a change in clinic policy
Number of subjects: 1315
Study 22700845 — intervention group
Group type: COMPARATOR
Intervention: Universal HIV testing
Number of subjects: 1315
Study 22700845 — intervention group
Group type: COMPARATOR
Intervention: Routine universal testing
Number of subjects: 1315
Study 21712533 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet and aerobic exercise training (LGI/EX)
Number of subjects: 15
Study 21712533 — intervention group
Group type: COMPARATOR
Intervention: High glycemic index diet and aerobic exercise training (HGI/EX)
Number of subjects: 15
Study 19627930 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback group
Number of subjects: 29
Study 19627930 — intervention group
Group type: COMPARATOR
Intervention: No feedback group
Number of subjects: 29
Study 16881940 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher literacy (>= 9th grade)
Number of subjects: 380
Study 16881940 — intervention group
Group type: COMPARATOR
Intervention: Low literacy (<= 8th grade)
Number of subjects: 380
Study 12050835 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice therapy before chest tube removal
Number of subjects: 50
Study 12050835 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 50
Study 10326359 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (purchase)
Number of subjects: 144
Study 10326359 — intervention group
Group type: COMPARATOR
Intervention: Control group (purchase/rent)
Number of subjects: 144
Study 7575134 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) inhalation, 800 micrograms/day, twice daily (group A)
Number of subjects: 33
Study 7575134 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) inhalation, 800 micrograms/day, four times daily (group B)
Number of subjects: 33
Study 1720012 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (600 mg iv as a single dose infused over several hours)
Number of subjects: 0
Study 1720012 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (oral administration, longer-term effects)
Number of subjects: 0
Study 1720012 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (double-blind cross-over study)
Number of subjects: 0
Study 7020779 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Relaxation (PR) with positive expectancy
Number of subjects: 48
Study 7020779 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Response (RR) with positive expectancy
Number of subjects: 48
Study 7020779 — intervention group
Group type: COMPARATOR
Intervention: No-treatment Control (C)
Number of subjects: 48
Study 31304986 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop on sensory processing disorders and behaviour management strategies; experience in a multi-sensory environment
Number of subjects: 9
Study 31304986 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-sensory environments
Number of subjects: 9
Study 28070979 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehension Booster programme for a 6-week period
Number of subjects: 38
Study 28070979 — intervention group
Group type: COMPARATOR
Intervention: Usual teaching
Number of subjects: 38
Study 25106731 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI (5-fluorouracil/leucovorin with irinotecan)
Number of subjects: 426
Study 25106731 — intervention group
Group type: EXPERIMENTAL
Intervention: IRIS (irinotecan plus S-1)
Number of subjects: 426
Study 25106731 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI (5-fluorouracil/leucovorin with irinotecan) in patients who received prior chemotherapy containing oxaliplatin
Number of subjects: 426
Study 25106731 — intervention group
Group type: EXPERIMENTAL
Intervention: IRIS (irinotecan plus S-1) in patients who received prior chemotherapy containing oxaliplatin
Number of subjects: 426
Study 23911170 — intervention group
Group type: EXPERIMENTAL
Intervention: PREDIRCAM eHealth platform
Number of subjects: 15
Study 21881929 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of the PLMA in the awake patient in the operating room close to the end of the procedure.
Number of subjects: 120
Study 21881929 — intervention group
Group type: COMPARATOR
Intervention: Removal of the PLMA in the recovery room when the patient was awake.
Number of subjects: 120
Study 16861597 — intervention group
Group type: EXPERIMENTAL
Intervention: MYTRI program implemented with more than 5,000 students
Number of subjects: 12484
Study 16439468 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR5‐stop polymorphism (dominant-negative)
Number of subjects: 215
Study 12646120 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified extract of Parietaria judaica pollen (depigmented and glutaraldehyde‐polymerized), treatment schedule: incremental phase of 5 injections and maintenance dosage of 0.5 ml per month, total of 14 injections over 12 months
Number of subjects: 30
Study 12646120 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific immunotherapy)
Number of subjects: 30
Study 10771448 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 10 mg day(-1)
Number of subjects: 0
Study 10771448 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 mg day(-1)
Number of subjects: 0
Study 10771448 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 40-80 mg day(-1)
Number of subjects: 0